EUVIMEDEUVIMED entdecken
Crossref

Comprehensive Analysis of Metastatic Prostate Cancer: Real-World Data From the Middle East

Ramiz Abu-Hijlih iD, Samer Salah iD, Haneen Abaza iD, Ayat Taqash iD, Hadeel Abdelkhaleq iD, Akram Al-Ibraheem iD, Amal Al-Omari iD

JCO Global Oncology · 2024

DOI: 10.1200/go.24.00042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Ramiz Abu-Hijlih und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Metastatic prostate cancer (Pca) is a complex disease with diverse clinical characteristics and outcomes across the geographical distribution. Herein, we present a series of patients from the Middle East, aiming at identifying disease outcomes and prognostic factors specific to this regional context. METHODS AND MATERIALS This is a retrospective study of patients with metastatic Pca, diagnosed at King Hussein Cancer Center, Jordan, between 2006 and 2018. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Factors that significantly affected overall survival (OS) in the univariable analysis were examined in a multivariable Cox regression analysis. RESULTS A total of 188 patients with metastatic Pca were included in this analysis, of whom 168 (89%) had de novo metastatic disease. The median age at diagnosis was 68 years, 144 (77%) had bone metastasis, 32 (17%) had visceral metastasis, and 126 (67%) had high-volume disease. At a median follow-up of 67 months, the median OS was 44.3 months. The following factors predicted inferior OS in univariable analysis: smoking, normal BMI, high-volume disease, high alkaline phosphatase (ALP), previous local therapy for prostate, and orchiectomy versus medical androgen deprivation therapy (ADT). On multivariable analysis, high-volume disease (hazard ratio [HR], 1.92 [95% CI, 1.17 to 3.13]; P = .0094), high ALP (HR, 2.136 [95% CI, 1.38 to 3.31]; P < .001), and orchiectomy (HR, 2.40 [95% CI, 1.51 to 3.82]; P < .001) emerged as independent factors for inferior OS. CONCLUSION Metastatic Pca outcomes in our population closely align with the global benchmark. High volume status, elevated ALP, and performance of surgical as opposed to medical ADT emerge as prognostic indicators of poor survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHumansMaleRetrospective StudiesAgedMiddle AgedJordanPrognosisMiddle EastNeoplasm MetastasisAndrogen AntagonistsAged, 80 and overBone NeoplasmsKaplan-Meier Estimate

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan.
  • Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
  • Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan.
  • Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.

ORCID-Profile: Ramiz Abu-Hijlih, Samer Salah, Haneen Abaza, Ayat Taqash, Hadeel Abdelkhaleq, Akram Al-Ibraheem, Amal Al-Omari

Zitieren

APA

Abu-Hijlih, R., Salah, S., Abaza, H., Taqash, A., Abdelkhaleq, H., Al-Ibraheem, A., & Al-Omari, A. (2024). Comprehensive Analysis of Metastatic Prostate Cancer: Real-World Data From the Middle East. JCO Global Oncology. https://doi.org/10.1200/go.24.00042

Vancouver

Abu-Hijlih R, Salah S, Abaza H, Taqash A, Abdelkhaleq H, Al-Ibraheem A, et al. Comprehensive Analysis of Metastatic Prostate Cancer: Real-World Data From the Middle East. JCO Global Oncology. 2024. doi:10.1200/go.24.00042

BibTeX
@article{AbuHijlih2024,
  author = {Abu-Hijlih, Ramiz and Salah, Samer and Abaza, Haneen and Taqash, Ayat and Abdelkhaleq, Hadeel and Al-Ibraheem, Akram and Al-Omari, Amal},
  title = {Comprehensive Analysis of Metastatic Prostate Cancer: Real-World Data From the Middle East},
  journal = {JCO Global Oncology},
  year = {2024},
  doi = {10.1200/go.24.00042}
}
Kostenlos starten →